

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

PRODUCT INFORMATION


FRISIUM

NAME OF MEDICINE

AUSTRALIAN APPROVED NAME

Clobazam

CHEMICAL STRUCTURE



Molecular Formula: $C_{16}H_{13}ClN_2O_2$

Molecular Weight: 300.74

Chemical Name: 7-Chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4(3H)-dione

CAS REGISTRY NUMBER

22316-47-8

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

DESCRIPTION

Clobazam is the first anxiolytic drug which belongs to the class of 1,5 rather than 1,4-benzodiazepines. Clobazam differs from the 1,4-benzodiazepines in that the nitrogen atoms in the 7-membered heterocyclic ring are located at positions 1 and 5 and an oxo substituent is located at position 4. This chemical difference confers both chemical and pharmacological properties upon clobazam which distinguish it from diazepam and other compounds of the 1,4-benzodiazepine series.

PHARMACOLOGY

Class

Clobazam is an anxiolytic of the benzodiazepine group.

Site and Mode of Action

Electrophysiological investigations have shown that the most important sites of action of the benzodiazepines are the limbic system, the thalamus and the spinal cord. At the synaptic level it has been proposed that various neurological systems including those utilising noradrenaline, dopamine, serotonin, acetylcholine, glycine and gamma-aminobutyric acid (GABA) as neurotransmitters may be involved in the mediation of the pharmacological effects.

PHARMACODYNAMICS

Evidence suggests that the observed decreased turnover rate of these various neurotransmitters can be explained in a unified way by a primary action of benzodiazepines on the GABA system through a facilitation of GABA-ergic neurotransmission. GABA is the major inhibitory neurotransmitter in the mammalian brain. In most brain regions GABA is the transmitter of postsynaptic inhibitions, but at certain brain stem synapses GABA mediates presynaptic inhibition. Benzodiazepines may enhance both of these actions of GABA.

Recent studies have demonstrated the presence of specific binding sites for benzodiazepines which are independent of GABA sites which occur exclusively in the central nervous system.

The concentration of the binding sites is highest in the cerebral and cerebellar cortex followed by areas of the limbic system, the basal ganglia and the brain stem. It remains to be demonstrated whether benzodiazepine receptors are associated with GABA synapses or whether they show a wider pattern of distribution.

Like the 1,4-benzodiazepines, Frisium has been found to be an effective antianxiety agent and produces approximately equivalent anxiolytic activity compared to diazepam when used on a 2:1

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION

March 2013

Frisium- - Clobazam 10mg Tablet

dosage basis (Frisium: diazepam). Frisium produces almost no muscular relaxation at normal dosage levels.

PHARMACOKINETICS

Absorption

After oral administration of ¹⁴C-labelled clobazam to man, approximately 90% of the radioactivity was recovered in the urine.

Distribution

Peak serum concentrations of clobazam occurred between one and four hours after oral administration, irrespective of the dose given. After a single 10 mg dose the peak serum concentration was found to be approximately 200 nanogram/mL. There are large differences between individuals in the levels reached. Approximately 85% of clobazam is bound to plasma proteins in the concentration range 50-10,000 nanogram/mL.

Metabolism

Clobazam is demethylated by CYP 3A4, and to a lesser extent by 2C19 and 2B6 to form the active metabolite N-desmethyl-clobazam (N-CLB), which itself is further metabolised by CYP 2C19 into 4'-hydroxy-N-desmethyl-clobazam.

The main urinary metabolites are N-desmethyl-clobazam and 4'-hydroxy-clobazam. In man, the plasma elimination phase of unchanged clobazam varies with age and sex. In one study, after a single dose of 20 mg, the following half-lives were observed :- young men 17 hours; young women 31 hours; elderly men 48 hours; elderly women 49 hours.

A steady level of clobazam in the plasma is reached within 1 week of initiating treatment or changing the dose. The plasma beta elimination phase of the major plasma metabolite, N-desmethyl-clobazam is considerably longer and is about 2 to 3 days for young men and women and 3 to 5 days for elderly men and women. It may increase with repeated doses. In a repeated dose study following administration of 10 mg clobazam twice daily for 28 days, the level of unchanged clobazam reached a steady state of 333 nanogram/mL within one week whereas the major serum metabolite took 28 days to reach a near steady state level about 8 times higher than that of unchanged clobazam and this was from 8.3 to 27.5 times higher than the metabolite level after a single dose. The levels fell slowly after the last dose from 2,811 nanogram/mL to 2,031 nanogram/mL on the 7th day.

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

Excretion

Over a two week period approximately 79% of a 20 mg oral dose of clobazam is excreted in the urine and 12% in the faeces as parent drug and/or metabolites.

Age and sex influence the metabolism of clobazam in that the total clearance of clobazam is significantly lower in the elderly male and elimination half life is extended in both the elderly male and female which leads to the accumulation of the parent compound and its active metabolite. Lower dosage should be given to these patients.

INDICATIONS

Adults

Short term use (up to one month) for the symptomatic management of acute anxiety and sleep disturbances associated with anxiety.

Children (4 years of age and over)

As adjunctive therapy in patients with partial refractory and Lennox-Gastaut epilepsy types who are not adequately stabilized with their current anticonvulsant therapy.

CONTRAINDICATIONS

- Hypersensitivity to clobazam or other benzodiazepines, or excipients.
- History of drug or alcohol dependence
- Myasthenia gravis
- Severe respiratory insufficiency or chronic obstructive airways disease with incipient respiratory failure.
- Sleep apnoea syndrome.
- Severe impairment of liver function
- Pregnancy (see 'Precautions' – Use in Pregnancy)
- Lactation (see 'Precautions' – Use in Lactation)

PRECAUTIONS

ALCOHOL AND CNS DEPRESSANT DRUGS

Patients should be advised that their tolerance for alcohol and other CNS depressants will be diminished and that these medications should either be eliminated or given in reduced dosage in the presence of clobazam.

Clobazam may potentiate the effects of CNS depressant drugs; therefore the administration of clobazam should be cautious in cases of acute intoxication with alcohol, hypnotics, analgesics, neuroleptics, antidepressants and lithium (See Interactions with other Medicines).

DEPENDENCE AND TOLERANCE

In general, benzodiazepines should be prescribed for short periods only (e.g. 2-4 weeks). Continuous long-term use of Frisium is not recommended. The use of benzodiazepines may lead to dependence as defined by the presence of a withdrawal syndrome on discontinuation of the drug. Tolerance as defined by a need to increase the dose in order to achieve the same anti-epileptic effect may occur in patients receiving long term recommended dose under medical supervision. Tolerance to sedation may occur with benzodiazepines, especially in those with drug seeking behaviour.

WITHDRAWAL

After as little as one week of therapy, withdrawal symptoms can appear following the cessation of recommended doses. Following the use of Frisium at therapeutic doses, withdrawal from the medication should be gradual. An individualised withdrawal timetable needs to be planned for each patient in whom dependence is known or suspected. The minimum time is probably four weeks, although programmes as long as four months have been suggested. As with all benzodiazepines, when treatment is suddenly withdrawn, a temporary increase of sleep disturbance can occur after use. A withdrawal syndrome may also occur when abruptly changing over from a benzodiazepine with a long duration of action (eg clobazam) to one with a short duration of action.

Withdrawal symptoms similar in character to those noted with barbiturates and alcohol have occurred following abrupt discontinuation of benzodiazepines. These symptoms range from headaches, sleep disturbances, increased dreaming, tension, restlessness, confusion, excitability, symptomatic psychoses (eg withdrawal delirium), numbness and tingling sensations in extremities, muscle pain, sweating, nausea and vomiting, hyperacusis, epileptic seizures, insomnia, anxiety, dysphonia, palpitations, panic attacks, vertigo, myoclonus, akinesia, hypersensitivity to light, sound and touch, abnormal body sensations, (e.g. feelings of motion, metallic taste), depersonalisation, derealisation, delusional beliefs, hyperreflexia and loss of short

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION

March 2013

Frisium- - Clobazam 10mg Tablet

term memory, to a major syndrome which may include convulsions, tremor, abdominal and muscle cramps, confusional state, delirium, hallucinations, hyperthermia, psychosis, vomiting and sweating. Such manifestations of withdrawal, especially the more serious ones are more common in patients who have received excessive doses over a prolonged period. However, withdrawal symptoms have been reported following abrupt discontinuation of benzodiazepines taken continuously at therapeutic levels. Accordingly Frisium should be terminated by tapering the dose to minimise occurrence of withdrawal symptoms. Patients should be advised to consult with their physician before either increasing the dose or abruptly discontinuing the medication.

Rebound phenomena have been described in the context of benzodiazepine use. Rebound insomnia, mood changes, anxiety or sleep disturbances and restlessness mean an increase in the severity of these symptoms beyond pre-treatment levels following cessation of benzodiazepines. Rebound phenomena in general possibly reflect re-emergence of pre-existing symptoms combined with withdrawal symptoms described earlier. Some patients prescribed benzodiazepines with very short half-lives (in the order of 2 to 4 hours) may experience relatively mild rebound symptoms in between their regular doses. Withdrawal/rebound symptoms may follow high doses for relatively short periods.

ABUSE

Caution must be exercised in administering clobazam to individuals known to be addiction prone or those whose history suggests they may increase the dosage on their own initiative. It is desirable to limit repeat prescription without adequate medical supervision.

DRIVING OR PERFORMING HAZARDOUS TASKS

Clobazam has been shown to have a less detrimental effect on psychomotor performance than 1,4 - benzodiazepines (diazepam, lorazepam) in experimental studies in volunteers at doses of 10 to 30mg/day.

However, as with all patients taking CNS-depressant medications, patients receiving Frisium should be warned not to operate dangerous machinery or motor vehicles until it is known that they do not become drowsy or dizzy from Frisium therapy. Abilities may be impaired on the day following use.

USE IN ELDERLY OR DEBILITATED PATIENTS

Dosage should be limited to the smallest effective amount to reduce the possibility of a fall due to sedation, giddiness, confusion or ataxia.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

HYPOTENSION

Although hypotension occurs uncommonly, clobazam should be administered with care to patients in whom a drop in blood pressure may lead to cardiac or cerebral complications. This is particularly important in elderly patients.

EPILEPSY

When benzodiazepines are administered to persons with convulsive disorders, there is a possibility that the frequency and/or severity of seizures may increase and require an adjustment of anticonvulsant medication (development of tolerance). There is some evidence that concurrent administration of clobazam with phenobarbitone, phenytoin or carbamazepine may marginally increase the blood levels of the anticonvulsants and also increase the rate of metabolism of clobazam. Increases in valproic acid levels with clobazam treatment, have also been observed in a study involving six patients. Therefore the blood levels of the anticonvulsants should be determined in such cases. Abrupt withdrawal of benzodiazepine should be avoided, as this may temporarily increase seizure frequency and severity.

AMNESIA

Amnesia, usually anterograde but extending sometimes to the period preceding drug administration, has been frequently reported after parenteral administration and less frequently after oral doses of benzodiazepines.

PARADOXICAL REACTIONS

Paradoxical reactions such as rage, stimulation or excitement may occur rarely with clobazam and are an indication to discontinue the drug.

MUSCLE WEAKNESS

Clobazam can cause muscle weakness. Therefore in patients with pre-existing muscle weakness or spinal or cerebellar ataxia, special observation is required and a dose reduction may be necessary.

Caution should be used in the treatment of patients with acute narrow-angle glaucoma (because of atropine-like side effects).

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

IMPAIRED RENAL/HEPATIC FUNCTION

In patients with impairment of renal and hepatic function, responsiveness to clobazam and susceptibility to adverse effects are increased, and a dose reduction may be necessary. In rare instances some patients taking benzodiazepines have had elevations of liver enzymes. In long-term treatment renal and hepatic function must be checked regularly.

BLOOD DYSCRASIAS

In rare instances some patients taking benzodiazepines have developed blood dyscrasias. As with other benzodiazepines, periodic blood counts are recommended.

DEPRESSION, PSYCHOSIS AND SCHIZOPHRENIA

Clobazam is not recommended as primary therapy in patients with depression and psychosis. In such conditions, psychiatric assessment and supervision are necessary if benzodiazepines are indicated. Benzodiazepines may increase depression in some patients and may contribute to deterioration in severely disturbed schizophrenics with confusion and withdrawal. Suicidal tendencies may be present or uncovered and protective measures may be required.

IMPAIRED RESPIRATORY FUNCTION

Caution in the use of clobazam is recommended in patients with respiratory depression and in patients with chronic or acute respiratory insufficiency. In patients with chronic obstructive pulmonary disease, benzodiazepines can cause increased arterial carbon dioxide tension and decreased oxygen tension. Respiratory function must be monitored and a dose reduction may be necessary.

CYP2C19 POOR METABOLIZERS

In patients who are CYP2C19 poor metabolizers, levels of the active metabolite N-desmethylclobazam are expected to be increased as compared to extensive metabolizers. Dosage adjustment of clobazam may be necessary (e.g. low starting dose with careful dose titration)

EFFECT ON FERTILITY

There has been no study done on effect of clobazam on human fertility.

Adequate fertility studies in animals are lacking. The available data shows no effects of oral clobazam on fertility in rats and mice.

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium - Clobazam 10mg Tablet

March 2013

USE IN PREGNANCY (CATEGORY C)

Benzodiazepines cross the placenta and may cause hypotonia, reduced respiratory function, respiratory depression, hypothermia and feeding difficulties (signs and symptoms of so-called “floppy infant syndrome”) in the newborn infant. Continuous treatment during pregnancy and administration of high doses in connection with delivery should be avoided. Withdrawal symptoms in newborn infants have been reported with this class of drugs. Appropriate monitoring of the newborn in the postnatal period is recommended.

Adequate embryofetal development studies in animals are lacking. The available data show no evidence for teratogenic effects following oral administration of clobazam to mice, rats and rabbits during the period of organogenesis. Increased embryofetal losses at high doses may have been secondary to maternal toxicity.

USE IN LACTATION

Clobazam may appear in the breast milk of nursing mothers and may cause drowsiness and feeding difficulties in the infant. For this reason, the use of Frisium in such circumstances cannot be recommended. Neonates are generally more susceptible to the toxic effects of benzodiazepines.

In limited studies, no effects on offspring development were reported following oral administration of clobazam to rats from late gestation to weaning.

PAEDIATRIC USE

Frisium tablets are not recommended for children for the treatment of anxiety or sleep disorders.

In a published, study oral administration of clobazam to rats during early development (postnatal days 14 to 48) at a dose of 120 mg/kg/day (16 fold the 30 mg paediatric clinical dose based on body surface area) was associated with effects on growth (decreased bone density and length) and behaviour. The effects on bone but not on behaviour were reversible when the drug was discontinued. The no adverse effect level in this study was 36 mg/kg/day (~5 fold the 30 mg paediatric clinical dose based on body surface area).

USE IN THE ELDERLY

Dosage should be limited to the smallest effective amount to reduce the possibility of a fall due to sedation, giddiness, confusion or ataxia. (see ‘Precautions’ - Tolerance and Dependence).

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

CARCINOGENICITY

The carcinogenic potential of clobazam has not been adequately assessed. In a limited study in rats oral administration of clobazam at doses of 4, 20 and 100 mg/kg/day for two years found an increased incidence of thyroid follicular cell adenoma in males at the high dose (30 fold the 30 mg adult clinical dose based on body surface area), thought to be due to enhanced hepatic thyroxine clearance. A limited study on mice treated with clobazam for 80 weeks did not show evidence of increased tumour incidence.

GENOTOXICITY

Clobazam was not genotoxic in a battery of in vitro (bacterial reverse mutation, mammalian forward mutation, chromosomal aberrations, unscheduled DNA synthesis) and in vivo (micronucleus test) assays.

EFFECT ON LABORATORY TESTS

Data not available.

INTERACTIONS WITH OTHER MEDICINES

Central nervous system depressant drugs

The benzodiazepines, including clobazam, produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression e.g. barbiturates, alcohol, sedatives, tricyclic antidepressants, non-selective MAO inhibitors, phenothiazines and other antipsychotics, skeletal muscle relaxants, antihistamines, hypnotics, narcotic analgesics, anxiolytics, anticonvulsants and anaesthetics (see Precautions). Special caution is also necessary when clobazam is administered in cases of intoxication with such substances or lithium.

The anticholinergic effects of other drugs including atropine and similar drugs, antihistamines and antidepressants may be potentiated.

CYP interactions

In vitro studies identified CYP 3A4 and 2C19 as the main isozymes involved in the oxidative metabolism of clobazam, and 2C19 further metabolises the active metabolite N-desmethylclobazam (N-CLB), highlighting potential interactions with known inducers or inhibitors of these isozymes.

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION

March 2013

Frisium- - Clobazam 10mg Tablet

Strong and moderate inhibitors of CYP2C19 may result in increased exposure to (N-CLB), and dosage adjustment of clobazam may be necessary when co-administered with strong (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate (e.g. omeprazole) CYP2C19 inhibitors.

Clobazam is a weak CYP2D6 inhibitor. Dose adjustment of drugs metabolized by CYP2D6 (e.g. dextromethorphan, pimozide, paroxetine, nebivolol) may be necessary.

Anticonvulsants

Interactions have been reported between some benzodiazepines and anticonvulsants, with changes in the serum concentration of the benzodiazepine or anticonvulsant. It is recommended that patients be observed for altered responses when benzodiazepines and anticonvulsants are prescribed together. ECG monitoring should be performed and serum level monitoring of the anticonvulsant be performed more frequently.

Minor EEG changes, usually low voltage fast activity, of no known clinical significance, has been reported with benzodiazepine administration.

In patients receiving concomitant treatment with valproic acid, there may be a slight to moderate rise in plasma valproic acid concentration. Phenytoin plasma levels may rise if patients receive concomitant treatment with clobazam. Where possible, it is recommended that blood levels of concomitantly administered valproic acid or phenytoin be monitored.

Carbamazepine and phenytoin may cause an increase in the metabolic conversion of clobazam to the active metabolite N-desmethyl clobazam.

Muscle relaxants

The effects of muscle relaxants and nitrous oxide may be enhanced.

Alcohol

Patients should be advised of possible interactions, especially with alcohol, as bioavailability of clobazam can be increased by 50%.

ADVERSE EFFECTS

The most common adverse effect reported in the Frisium clinical trials was sedation/tiredness/drowsiness occurring in 32% as compared to 43% given diazepam and 22% on placebo. The following side effects occurred in more than 1% of patients in the reported double blind studies.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

CARDIOVASCULAR

Hypotension (1.2%).

DERMATOLOGICAL

Rash (1.4%).

GASTRO-INTESTINAL

Dry mouth (3.2%), constipation (2.1%), diarrhoea (1.4%), nausea (1.3%).

NERVOUS SYSTEM

Sedation/tiredness/drowsiness (32%), dizziness/ataxia (8.2%), headache (3.6%), insomnia (1.8%), confusion (1.6%), slurred speech (1.6%), tremor (1.3%).

PSYCHIATRIC

Depression (3.5%), irritability (1.5%).

Clinical adverse experiences occurring since the drug was marketed or occurring in less than 1% of patients in the controlled studies are listed below.

GASTROINTESTINAL

Vomiting, decreased appetite

GENERAL

Weight gain, sweating, hang-over, anorexia, slowed or indistinct speech (disorders of articulation) and fall.

GENITOURINARY

Decreased libido or loss of libido.

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

MUSCULOSKELETAL

Muscle aches and weakness, stiffness or spasm, unsteady movement, slowing of reaction time, fine tremor of fingers, unsteadiness of gait and other motor functions.

SKIN AND SUBCUTANEOUS TISSUE DISORDERS

Urticaria, pruritus, Rash, Stevens-Johnson syndrome, Toxic Epidermal Necrolysis

NERVOUS SYSTEM

Amnesia, euphoria, agitation, numbed emotions, anterograde amnesia, pre-existing depression may be unmasked during benzodiazepine use.

EYE DISORDERS

Visual disorders (Blurred vision, diplopia, nystagmus).

LABORATORY TESTS

Abnormal liver function tests and haematology.

RESPIRATORY

Respiratory depression, particularly in patients with pre-existing compromised respiratory function (eg bronchial asthma) or brain damage, respiratory insufficiency may occur or deteriorate.

PARADOXICAL REACTIONS

Especially in the elderly and in children, paradoxical reactions may occur, such as restlessness, difficulty in falling asleep or sleeping through, irritability, acute agitational states, anxiety, aggressiveness, delusion, fits of rage, nightmares, hallucinations, psychotic reactions, suicidal tendencies, frequent muscle spasms, insomnia. In the event of such reactions, treatment with Frisium must be discontinued.

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet

March 2013

DEPENDENCE AND TOLERANCE

May develop, especially with prolonged use. Impairment of consciousness, sometimes combined with respiratory disorders, may occur in rare cases, and sometimes persist for a considerable length of time.

DOSAGE AND ADMINISTRATION

Where possible benzodiazepines should not be administered over prolonged periods. Frisium is approved for short term use only (up to one month) in the treatment of anxiety and sleep disorders.

The 10mg tablets can be divided into equal halves of 5mg.

Anxiety states and Sleep Disorders:

Adults

The usual dose is 10 to 30 mg daily (1 to 3 tablets) in a single or divided dosage. Doses of up to 60 to 80 mg daily have been used in the treatment of hospitalised adult patients with severe anxiety states. Due regard must be paid to the possibility of interference with alertness and reaction time. The fundamental principle is to keep the dose as low as possible.

Geriatric patients may be given one 10 mg tablet once or twice daily. Increased responsiveness and higher susceptibility to adverse effects may be present in elderly patients and require low initial doses and gradual dose increments under careful observation.

It should be kept in mind that after each change in dosage, a new steady state plasma level will not be reached for several days for clobazam itself and longer for its principal metabolite.

Patients with impairment of renal or hepatic function: Increased responsiveness and higher susceptibility to adverse effects may be present in these patients and require low initial doses and gradual dose increments under careful observation.

Discontinuation of treatment: **It is strongly recommended that after prolonged treatment clobazam is not withdrawn suddenly but rather that the dose is reduced gradually under medical supervision.**

Children

Frisium tablets are not recommended for children for the treatment of anxiety or sleep disorders.

Adjunctive therapy in Partial Refractory Epilepsy .

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION

March 2013

Frisium- - Clobazam 10mg Tablet

The patient must be re-assessed after a period not exceeding four weeks and regularly thereafter in order to evaluate the need for continued treatment

Children (4 years of age and over)

The following dosage regime is recommended as an addition to the patient's current antiepileptic therapy.

It is recommended that normally treatment be started at 5 mg daily. A maintenance dose of 0.3 to 1.0 mg/kg body weight daily is usually sufficient.

The possible interference with alertness and reaction time must be taken into account. The fundamental principle is to keep the dose as low as possible. Constant doses and intermittent therapy, discontinuing clobazam and subsequently prescribing it again, have proved effective. If the daily dose is divided, the higher proportion should be taken at night.

Daily doses up to 30mg may be taken as a single dose at night.

As with other benzodiazepines, the possibility of a decrease in anticonvulsant efficacy during the course of treatment should be borne in mind.

OVERDOSAGE

Overdosage of benzodiazepines is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion and lethargy. In more serious cases symptoms may include ataxia, hypotonia, hypotension, respiratory depression, coma and very rarely death

Treatment : In the management of overdosage with any medication, it should be borne in mind that multiple agents may have been taken. Activated charcoal should be given to reduce absorption if the patient is conscious. Hypotension and respiratory depression should be managed according to general principles. Haemoperfusion and haemodialysis are not useful in benzodiazepine intoxication. The benzodiazepine antagonist flumazenil may be useful in hospitalised patients for the reversal of acute benzodiazepine effects. Please consult the flumazenil product information prior to usage.

For information on the management of overdose, contact the Poison Information Centre on 131126.

PRESENTATION AND STORAGE CONDITIONS

10 mg white, round, scored tablets marked B/GL with Hoechst logo on reverse.
Supplied in packs of 50 tablets.

Attachment 1: Product information for AusPAR Frisium Sanofi-Aventis Australia Pty Ltd PM-2011-04302-3-1 Final 3 October 2013. This Product Information was approved at the time this AusPAR was published.

PRODUCT INFORMATION
Frisium- - Clobazam 10mg Tablet
Store below 30°C.

March 2013

NAME AND ADDRESS OF THE SPONSOR

sanofi-aventis australia pty ltd

12-24 Talavera Road

Macquarie Park NSW 2113

POISON SCHEDULE OF THE MEDICINE

Schedule 4. (Prescription Only Medicine)

DATE OF FIRST INCLUSION IN THE ARTG

1 September 1993

DATE OF MOST RECENT AMENDMENT

14 May 2013